Nanomedicines—A Scientific Toy or an Emerging Market?

Wacker, Matthias G.

doi:10.1007/978-3-319-41421-8_18

Cited by 7 publications

(7 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intensity mean average size of PHB–sorafenib–doxorubicin nanoparticles was 199.3 ± 6.5 nm with a monodisperse distribution ( Figure 2 ) and low polydispersity index (0.071 ± 0.016). The size was increased by PEGylation, however, with the value of 250.5 ± 5.2 nm (polydispersity index: 0.155 ± 0.017) the PEGylated PHB–sorafenib–doxorubicin nanoparticles still remained in the desirable size range of polymeric nanoparticles, which is 50–300 nm, since the smaller ones can be rapidly excreted by the kidneys, while particles >300 nm are quickly recognized by the macrophages of the reticuloendothelial system [ 33 ].…”

Section: Resultsmentioning

confidence: 99%

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Babos

Rydz

Kawalec

et al. 2020

IJMS

View full text Add to dashboard Cite

Dual drug-loaded nanotherapeutics can play an important role against the drug resistance and side effects of the single drugs. Doxorubicin and sorafenib were efficiently co-encapsulated by tailor-made poly([R,S]-3-hydroxybutyrate) (PHB) using an emulsion–solvent evaporation method. Subsequent poly(ethylene glycol) (PEG) conjugation onto nanoparticles was applied to make the nanocarriers stealth and to improve their drug release characteristics. Monodisperse PHB–sorafenib–doxorubicin nanoparticles had an average size of 199.3 nm, which was increased to 250.5 nm after PEGylation. The nanoparticle yield and encapsulation efficiencies of drugs decreased slightly in consequence of PEG conjugation. The drug release of the doxorubicin was beneficial, since it was liberated faster in a tumor-specific acidic environment than in blood plasma. The PEG attachment decelerated the release of both the doxorubicin and the sorafenib, however, the release of the latter drug remained still significantly faster with increased initial burst compared to doxorubicin. Nevertheless, the PEG–PHB copolymer showed more beneficial drug release kinetics in vitro in comparison with our recently developed PEGylated poly(lactic-co-glycolic acid) nanoparticles loaded with the same drugs.

show abstract

Section: Resultsmentioning

confidence: 99%

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Babos

Rydz

Kawalec

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Due to the enhanced permeability and retention (EPR) effect, these nanoparticles may be capable of targeting tumor tissues [17]. While smaller nanoparticles can be rapidly excreted by the kidneys, larger colloids with a size of more than 300 nm are quickly recognized by the macrophages of the reticuloendothelial system [11]. Among other aspects, the encapsulation efficiency and particle size play an important role in nanocarrier delivery.…”

Section: Resultsmentioning

confidence: 99%

“…Recently, targeted nanotherapeutic formulations successfully passed phase 1 clinical trials [10]. A major shortcoming of nanocarrier delivery is limited drug loading, resulting in high excipient concentrations and administration volume [11].…”

Section: Introductionmentioning

confidence: 99%

Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques

et al. 2019

View full text Add to dashboard Cite

Today, efficient delivery of sorafenib to hepatocellular carcinoma remains a challenge for current drug formulation strategies. Incorporating the lipophilic molecule into biocompatible and biodegradable theranostic nanocarriers has great potential for improving the efficacy and safety of cancer therapy. In the present study, three different technologies for the encapsulation of sorafenib into poly(d,l-lactide-co-glycolide) and polyethylene glycol-poly(d,l-lactide-co-glycolide) copolymers were compared. The particles ranged in size between 220 and 240 nm, with encapsulation efficiencies from 76.1 ± 1.7% to 69.1 ± 10.1%. A remarkable maximum drug load of approximately 9.0% was achieved. Finally, a gadolinium complex was covalently attached to the nanoparticle surface, transforming the nanospheres into theranostic devices, allowing their localization using magnetic resonance imaging. The manufacture of sorafenib-loaded nanoparticles alongside the functionalization of the particle surface with gadolinium complexes resulted in a highly efficacious nanodelivery system which exhibited a strong magnetic resonance imaging signal, optimal stability features, and a sustained release profile.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques

Feczkó¹,

Piiper²,

Pleli³

et al. 2020

Updates in Pharmacology

View full text Add to dashboard Cite

Author Contributions: T.F. designed and achieved most of the experiments except cellular studies, and wrote the paper. A.P. designed the cellular studies and took part in the manuscript preparation. T.P., C.S., D.D. and T.J.V. performed the cytotoxicity and cellular uptake studies by MTT and flow cytometry, respectively. S.H. and F.R. designed and did the cellular uptake investigations by fluorescence microscopy. M.G.W. participated in designing the experiments and writing the manuscript.

show abstract

Nanomedicines—A Scientific Toy or an Emerging Market?

Cited by 7 publications

References 60 publications

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques

Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques

Contact Info

Product

Resources

About